Is inflammation the critical factor linking vulnerable coronary plaques to clinical coronary disease?

American Journal of Medicine

Volumn 114, Issue 7, 2003, Pages 607-608

  Buja, L Maximilian ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHEMOKINE; COLLAGEN; CYTOKINE; ELASTIN; GLYCOSAMINOGLYCAN; LOW DENSITY LIPOPROTEIN; METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR;

ANGIOCARDIOGRAPHY; ATHERECTOMY; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CORONARY ARTERY; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; DIABETES MELLITUS; DISEASE COURSE; EDITORIAL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; T LYMPHOCYTE; UNSTABLE ANGINA PECTORIS;

EID: 0037716829     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(03)00136-0     Document Type: Editorial

References (17)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 340:1999;115-126.
2. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation. 105:2002;1135-1143.
3. Farmer J.A., Gotto A.M. Jr. Dyslipidemia and the vulnerable plaque. Prog Cardiovasc Dis. 44:2002;415-428.
4. Willerson J.T. Systemic and local inflammation in patients with unstable atherosclerotic plaques. Prog Cardiovasc Dis. 44:2002;469-478.
5. Reape T.J., Groot P.H.E. Chemokines and atherosclerosis. Atherosclerosis. 147:1999;213-225.
6. Ridker P.M., Rifai N., Clearfield M., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 344:2001;1959-1965.
7. Pasceri V., Chang J., Willerson J.T., et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 103:2001;2531-2534.
8. Prasad A., Zhu J., Halcox J.P., et al. Predisposition to atherosclerosis by infections role of endothelial dysfunction . Circulation. 106:2002;184-190.
9. Kalayoglu M.V., Libby P., Byrne G.I. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA. 288:2002;2724-2731.
10. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 104:2001;365-372.
11. Geng Y.J., Libby P. Progression of atheroma a struggle between death and procreation . Arterioscler Thromb Vasc Biol. 22:2002;1370-1380.
12. van der Wal A.C., Becker A.E. Atherosclerotic plaque rupture - pathologic basis of plaque stability and instability. Cardiovasc Res. 41:1999;334-344.
13. Becker R.C. Antithrombotic therapy after myocardial infarction. N Engl J Med. 347:2002;1019-1022.
14. Meuwissen M., van der Wal A.C., Koch K.T., et al. Association between complex coronary artery stenosis and unstable angina and the extent of plaque inflammation. Am J Med. 114:2003;521-527.
15. Kwak B., Mach F. Statins inhibit leukocyte recruitment new evidence of their anti-inflammatory properties . Arterioscler Thromb Vasc Biol. 21:2001;1256-1258.
16. Eto M., Kozai T., Cosentino F., Joch H., Luscher T.F. Statin prevents tissue factor expression in human endothelial cells role of Rho/Rho-kinase and Akt pathways . Circulation. 105:2002;1756-1759.
17. Yoshida M., Sawada T., Ishii H., et al. HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro. Arterioscler Thromb Vasc Biol. 21:2001;1165-1171.